Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 3/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 14/20 | 0.39 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.39 |
| ▸ | ICMT | O60725 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16496878 | 0.90 | RIPK1 (0.43) | PIK3CDRIPK1ACVRL1 | |
| SCHEMBL5076719 | 0.84 | ACVRL1 (0.42) | PIK3CDRIPK1ACVRL1 | |
| SCHEMBL5077185 | 0.83 | RIPK1 (0.46) | RIPK1 | |
| SCHEMBL5077230 | 0.82 | PIK3CD (0.47) | PIK3CDRIPK1ACVRL1 | |
| SCHEMBL5074942 | 0.82 | PIK3CD (0.51) | PIK3CDRIPK1ACVRL1 | |
| SCHEMBL14312723 | 0.82 | RIPK1 (0.46) | PIK3CDRIPK1 | |
| SCHEMBL5076831 | 0.81 | ACVRL1 (0.42) | PIK3CDRIPK1ACVRL1 | |
| SCHEMBL5074925 | 0.81 | PIK3CD (0.43) | PIK3CDRIPK1ACVRL1 | |
| SCHEMBL5141007 | 0.81 | RIPK1 (0.46) | PIK3CDRIPK1 | |
| SCHEMBL14312843 | 0.81 | RIPK1 (0.43) | PIK3CDRIPK1ACVRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294776-A1 | Pyrrolo[2,1-F] [1,2,4] Triazin-4-Ylamines IGF-1R Kinase Inhibitors for the Treatment of Cancer and Other Hyperproliferative Diseases | BAYER HEALTHCARE AG (DE) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294776-A1 | Pyrrolo[2,1-F] [1,2,4] Triazin-4-Ylamines IGF-1R Kinase Inhibitors for the Treatment of Cancer and Other Hyperproliferative Diseases | IGF1R, FGFR1, IGFBP1 | PIK3CD 140/4885RIPK1 1367/4885ACVRL1 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.